Which has better earnings and valuation, ITGR or IRMD?

Integer has higher revenue and earnings than iRadimed. Integer is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.31 $102.81M $3.66 34.44 iRadimed $83.81M 12.55 $22.48M $1.79 45.93

Is ITGR or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to Integer's net margin of 6.97%. iRadimed's return on equity of 23.45% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% iRadimed 26.70% 23.45% 20.36%

Does the media prefer ITGR or IRMD?

In the previous week, Integer had 3 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Integer and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat Integer's score of 0.20 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRMD or IRTC?

In the previous week, iRadimed had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 4 mentions for iRadimed and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat iRadimed's score of 0.99 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IRMD or PLSE?

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 12.55 $22.48M $1.79 45.93 Pulse Biosciences $350K 10,502.12 -$72.78M -$1.18 N/A

Is IRMD or PLSE more profitable?

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media refer more to IRMD or PLSE?

In the previous week, Pulse Biosciences had 9 more articles in the media than iRadimed. MarketBeat recorded 13 mentions for Pulse Biosciences and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat Pulse Biosciences' score of 0.94 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IRMD or TMDX?

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 12.55 $22.48M $1.79 45.93 TransMedics Group $668.47M 4.25 $190.29M $3.89 21.13

Does the media refer more to IRMD or TMDX?

In the previous week, TransMedics Group had 11 more articles in the media than iRadimed. MarketBeat recorded 15 mentions for TransMedics Group and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat TransMedics Group's score of 0.92 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ATRC or IRMD?

iRadimed has lower revenue, but higher earnings than AtriCure. iRadimed is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $569.62M 4.87 -$11.45M $0.21 259.71 iRadimed $83.81M 12.55 $22.48M $1.79 45.93

Is ATRC or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to AtriCure's net margin of 1.85%. iRadimed's return on equity of 23.45% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% iRadimed 26.70% 23.45% 20.36%

Does the media refer more to ATRC or IRMD?

In the previous week, AtriCure had 8 more articles in the media than iRadimed. MarketBeat recorded 12 mentions for AtriCure and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat AtriCure's score of 0.88 indicating that iRadimed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iRadimed (IRMD) Competitors

$82.22 +0.35 (+0.43%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$82.12 -0.11 (-0.13%)

As of 09/11/2026 07:30 PM Eastern

Compare

IRMD vs. ITGR, IRTC, PLSE, TMDX, and ATRC

Should you buy iRadimed stock or one of its competitors? iRadimed's main competitors and comparable companies include Integer (ITGR), iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), TransMedics Group (TMDX), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRadimed compare to Integer?

Integer (NYSE:ITGR) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Integer has higher revenue and earnings than iRadimed. Integer is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.31	$102.81M	$3.66	34.44
iRadimed	$83.81M	12.55	$22.48M	$1.79	45.93

99.3% of Integer shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Integer currently has a consensus target price of $109.86, suggesting a potential downside of 12.86%. iRadimed has a consensus target price of $120.00, suggesting a potential upside of 45.95%. Given iRadimed's stronger consensus rating and higher possible upside, analysts clearly believe iRadimed is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Integer had 3 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Integer and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat Integer's score of 0.20 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a net margin of 26.70% compared to Integer's net margin of 6.97%. iRadimed's return on equity of 23.45% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
iRadimed	26.70%	23.45%	20.36%

Integer has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

iRadimed beats Integer on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRadimed (NASDAQ:IRMD) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 45.95%. iRhythm Technologies has a consensus price target of $179.93, suggesting a potential upside of 61.47%. Given iRhythm Technologies' higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRadimed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

In the previous week, iRadimed had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 4 mentions for iRadimed and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.44 beat iRadimed's score of 0.99 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.3% of iRadimed shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

iRadimed has a net margin of 26.70% compared to iRhythm Technologies' net margin of -1.69%. iRadimed's return on equity of 23.45% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
iRhythm Technologies	-1.69%	10.11%	1.53%

iRadimed has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.55	$22.48M	$1.79	45.93
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A

Summary

iRadimed beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does iRadimed compare to Pulse Biosciences?

iRadimed (NASDAQ:IRMD) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

iRadimed has a net margin of 26.70% compared to Pulse Biosciences' net margin of -6,755.78%. iRadimed's return on equity of 23.45% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

iRadimed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Pulse Biosciences had 9 more articles in the media than iRadimed. MarketBeat recorded 13 mentions for Pulse Biosciences and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat Pulse Biosciences' score of 0.94 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed currently has a consensus target price of $120.00, suggesting a potential upside of 45.95%. Pulse Biosciences has a consensus target price of $45.25, suggesting a potential downside of 14.80%. Given iRadimed's stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.55	$22.48M	$1.79	45.93
Pulse Biosciences	$350K	10,502.12	-$72.78M	-$1.18	N/A

Summary

iRadimed beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

How does iRadimed compare to TransMedics Group?

iRadimed (NASDAQ:IRMD) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

iRadimed currently has a consensus target price of $120.00, suggesting a potential upside of 45.95%. TransMedics Group has a consensus target price of $124.18, suggesting a potential upside of 51.11%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

iRadimed has a net margin of 26.70% compared to TransMedics Group's net margin of 22.69%. iRadimed's return on equity of 23.45% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
TransMedics Group	22.69%	15.88%	5.95%

iRadimed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.55	$22.48M	$1.79	45.93
TransMedics Group	$668.47M	4.25	$190.29M	$3.89	21.13

In the previous week, TransMedics Group had 11 more articles in the media than iRadimed. MarketBeat recorded 15 mentions for TransMedics Group and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat TransMedics Group's score of 0.92 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRadimed beats TransMedics Group on 9 of the 17 factors compared between the two stocks.

How does iRadimed compare to AtriCure?

AtriCure (NASDAQ:ATRC) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, AtriCure had 8 more articles in the media than iRadimed. MarketBeat recorded 12 mentions for AtriCure and 4 mentions for iRadimed. iRadimed's average media sentiment score of 0.99 beat AtriCure's score of 0.88 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of AtriCure shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 34.6% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AtriCure has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

iRadimed has a net margin of 26.70% compared to AtriCure's net margin of 1.85%. iRadimed's return on equity of 23.45% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
iRadimed	26.70%	23.45%	20.36%

AtriCure presently has a consensus target price of $52.00, indicating a potential downside of 4.66%. iRadimed has a consensus target price of $120.00, indicating a potential upside of 45.95%. Given iRadimed's stronger consensus rating and higher possible upside, analysts clearly believe iRadimed is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

iRadimed has lower revenue, but higher earnings than AtriCure. iRadimed is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$569.62M	4.87	-$11.45M	$0.21	259.71
iRadimed	$83.81M	12.55	$22.48M	$1.79	45.93

Summary

iRadimed beats AtriCure on 10 of the 16 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.05B	$5.38B	$7.14B	$12.72B
Dividend Yield	0.98%	1.79%	2.56%	11.15%
P/E Ratio	45.93	25.09	275.24	25.29
Price / Sales	12.55	82.90	656.02	98.94
Price / Cash	44.04	32.53	77.04	51.44
Price / Book	11.05	5.97	10.33	6.20
Net Income	$22.48M	$150.75M	$3.50B	$358.50M
7 Day Performance	-1.47%	-2.83%	-3.32%	-2.35%
1 Month Performance	-5.93%	-3.09%	-0.41%	-2.77%
1 Year Performance	15.36%	9.34%	19.21%	7.63%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	3.2619 of 5 stars	$82.22 +0.4%	$120.00 +45.9%	+10.7%	$1.05B	$83.81M	45.93	110	Analyst Upgrade Insider Trade High Trading Volume
ITGR Integer	2.5072 of 5 stars	$126.40 -0.1%	$109.86 -13.1%	+21.1%	$4.30B	$1.84B	34.54	11,000	Insider Trade Options Volume
IRTC iRhythm Technologies	3.8705 of 5 stars	$120.65 -2.0%	$179.93 +49.1%	-38.4%	$3.97B	$747.14M	N/A	2,400	Positive News
PLSE Pulse Biosciences	1.7098 of 5 stars	$50.17 -5.8%	$45.25 -9.8%	+251.7%	$3.45B	$1.19M	N/A	140	News Coverage Positive News Analyst Upgrade
TMDX TransMedics Group	4.244 of 5 stars	$88.18 -2.0%	$124.18 +40.8%	-29.8%	$3.05B	$605.49M	22.71	210	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. ITGR, IRTC, PLSE, TMDX, and ATRC

How does iRadimed compare to Integer?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to Pulse Biosciences?

Summary

How does iRadimed compare to TransMedics Group?

Summary

How does iRadimed compare to AtriCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. ITGR, IRTC, PLSE, TMDX, and ATRC

How does iRadimed compare to Integer?

Which has better earnings and valuation, ITGR or IRMD?

Do institutionals and insiders have more ownership in ITGR or IRMD?

Do analysts rate ITGR or IRMD?

Does the media prefer ITGR or IRMD?

Is ITGR or IRMD more profitable?

Which has more volatility & risk, ITGR or IRMD?

Summary

How does iRadimed compare to iRhythm Technologies?

Do analysts prefer IRMD or IRTC?

Which has more risk & volatility, IRMD or IRTC?

Does the media favor IRMD or IRTC?

Do institutionals & insiders hold more shares of IRMD or IRTC?

Is IRMD or IRTC more profitable?

Which has preferable valuation & earnings, IRMD or IRTC?

Summary

How does iRadimed compare to Pulse Biosciences?

Is IRMD or PLSE more profitable?

Do insiders & institutionals hold more shares of IRMD or PLSE?

Which has more volatility and risk, IRMD or PLSE?

Does the media refer more to IRMD or PLSE?

Do analysts rate IRMD or PLSE?

Which has better valuation & earnings, IRMD or PLSE?

Summary

How does iRadimed compare to TransMedics Group?

Do analysts rate IRMD or TMDX?

Do insiders & institutionals hold more shares of IRMD or TMDX?

Is IRMD or TMDX more profitable?

Which has more volatility and risk, IRMD or TMDX?

Which has better valuation & earnings, IRMD or TMDX?

Does the media refer more to IRMD or TMDX?

Summary

How does iRadimed compare to AtriCure?

Does the media refer more to ATRC or IRMD?

Do insiders & institutionals have more ownership in ATRC or IRMD?

Which has more volatility and risk, ATRC or IRMD?

Is ATRC or IRMD more profitable?

Do analysts recommend ATRC or IRMD?

Which has stronger earnings and valuation, ATRC or IRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools